Genprex, Inc. has issued a press release detailing new peer-reviewed research that underscores the importance of the TUSC2 tumor suppressor gene in maintaining healthy brain aging. This research, published in Mechanisms of Ageing and Development, could have far-reaching implications for both cancer treatment and understanding neurodegenerative diseases.
The study, conducted by researchers at Meharry Medical College, found that the absence of TUSC2 in mice led to significant disruptions in mitochondrial function and protein homeostasis, particularly affecting neuronal communication within the hippocampus. This region of the brain is crucial for learning and memory, and the effects were notably more pronounced in male mice compared to females, suggesting that there are important sex-specific differences in how TUSC2 deficiency impacts brain health.
Background
Genprex, Inc. operates in the pharmaceutical preparations sector, focusing on innovative gene therapies for cancer treatment. The company trades under the ticker GNPX on the Nasdaq. Recent filings include an 8-K on October 21, 2026, detailing the new research findings, as well as previous 8-Ks and a 10-Q from August 2026.
What the Filing Says
According to the filing, "On October 21, 2026, Genprex, Inc. issued a press release highlighting new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular processes associated with healthy brain aging." The study indicates that TUSC2 expression declines with age in various brain regions, including those affected by Alzheimer's disease.
Impact
This research could affect various stakeholders, including researchers in the pharmaceutical industry, healthcare providers, and patients. The findings suggest that TUSC2 may play a foundational role in brain health, potentially influencing future therapeutic approaches for age-related cognitive disorders and cancer treatments.
What's Next
The filing does not say what happens next.